• 3476 Citations
1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Korenblat performs patient based research in nonalcoholic fatty liver disease, portal hypertension and liver transplantation. His clinical practice is directed to the management of all forms of liver disease and liver transplant patients, with particular interest in nonalcoholic fatty liver disease, hepatocellular cancer, Wilson’s Disease and hereditary hemochromatosis.

Areas of Clinical Interest

Liver diseases, fatty liver disease, viral hepatitis, liver transplantation, metabolic liver disease

Fingerprint Dive into the research topics where Kevin Korenblat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 22 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 3476 Citations
  • 39 Article
  • 4 Review article
  • 3 Chapter
  • 1 Comment/debate

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

IDN-6556-14 Investigators , May 2020, In : Journal of Hepatology. 72, 5, p. 885-895 11 p.

Research output: Contribution to journalArticle

  • 9 Scopus citations

    A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment

    George, N., Liapakis, A. M., Korenblat, K. M., Li, T., Roth, D., Yee, J., Fowler, K. J., Howard, L., Liu, J. & Politi, M. C., Jul 1 2019, In : Kidney Medicine. 1, 4, p. 200-206 7 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Expanding the donor pool for lung transplantation using HCV-positive donors

    Kulkarni, H. S., Korenblat, K. M. & Kreisel, D., Jan 1 2019, In : Journal of Thoracic Disease. 11, p. S1942-S1946

    Research output: Contribution to journalComment/debate

    Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

    REGENERATE Study Investigators, Dec 14 2019, In : The Lancet. 394, 10215, p. 2184-2196 13 p.

    Research output: Contribution to journalArticle

  • 89 Scopus citations

    Resolution of Murine Toxic Hepatic Injury Quantified With Ultrasound Entropy Metrics

    Marsh, J. N., Korenblat, K. M., Liu, T. C., McCarthy, J. E. & Wickline, S. A., Oct 2019, In : Ultrasound in Medicine and Biology. 45, 10, p. 2777-2786 10 p.

    Research output: Contribution to journalArticle